Please find enclosed herewith the Outcome of the Board Meeting held on November 5, 2026.

67— GPT Healthcare Limited g P Regd. Office: GPT Centre, JC-25, Sector lll, Salt Lake, Kolkata —700 106, India CIN : L70101WB1989PLC047402 Phone : +91-33-4050-7000, Email : info@gptgroup.co.in, Visit us: www.gptgroup.co.in GPTHEALTH/CS/SE/2026-27 November 5, 2026 The Department of Corporate Services National Stock Exchange of India Limited BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Dalal Street Mumbai - 400 051 Mumbai - 400001 Scrip Symbol: GPTHEALTH Scrip Code: 544131 ISIN: INE486R01017 Dear Sir/Madam Sub: Outcome of Board Meeting held on November 5, 2026: In continuation of our letter dated October 27, 2026, intimating the date of Board meeting and with reference to the captioned subject and pursuant to Regulation 30, 33, 42 and Regulation 43 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of GPT Healthcare Limited (“the Company”) had at its meeting held today i.e., Thursday, November 5, 2026, inter alia considered and approved the following matters amongst others: 1. Approved the Un-Audited Financial Results of the Company for the 2"! quarter and half year ended September 30, 2026, which has been duly reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the Listing Regulations, the said Financial Results along with Limited Review Report thereon issued by Statutory Auditors of the Company are being submitted herewith as annexure to this outcome; Since the Company does not have any subsidiary / associate, there is no requirement for submitting Consolidated Financial Results for the 2" quarter and half year ended September 30, 2026. 2. Declared Interim Dividend @10% (X 1/- per equity share) for the Financial Year 2026-27 and pursuant to Regulation 42 of the Listing Regulations, the Board has fixed Thursday, November 12, 2026 as the “Record Date” to ascertain the names of the shareholders / beneficial owners of the Company to whom the aforesaid interim dividend shall be payable. The Company is expecting to pay the interim dividend to the shareholders on or before December 4, 2026. The said results will be duly published in the newspaper as required by Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and will also be uploaded on the website of the company at www.ilshospitals.com. The Board Meeting commenced at 3:30 P.M. and concluded at 4:15 P.M. We request you to kindly take the same on records. This is for your information and records. Thanking You, Yours sincerely, For GPT Healthcare Limited Ankur Sharma Company Secretary and Compliance Officer M. No A31833 Encl: A/a S.R BaruBoi & Co. LLP S oo et Chartered Accountants Kolkata - 700 016, India Tel : +91 33 6134 4000 Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Lit ing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors GPT Healthcare Limited We have reviewed the accompanying statement of unaudited financial results of GPT Healthcare Limited (the “Company”) for the quarter ended September 30, 2026 and year to date from April 1, 2026 to September 30, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”). The Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company’s Board ofD irectors. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 oft he Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For S.R. BATLIBOI & Co. LLP Chartered Aécoyntants ICAI Firm registration number: 301003E/E300005 per Sanjay Kumar Agarwal Partner Membership No.: 060352 UD[N:160603S2ZDHSEM TIOE Place: Kolkata Date: November 05, 2026 S.R. Batlibol & Co. LLP, a Limited Liability Partnership with LLP Identity No. AAB-4294 Reqd. Office : 22, Camat Street, Block ‘8", 3rd Floor, Kolkata700 016 GPT HEALTHCARE LIMITED Registered Office: GPT Centre, JC-25, Sector 11t Salt Lake City, Kolkata - 700 106, India «G-P-F CIN : L70101WB1989PLCO47402, Website: www.i lshospitals.com, Email : ghl.cosec@gptgroup.co.in Statement Of Unaudited Financial Results for the quarter and half year ended September 30, 2026 (% in lakhs unless otherwise stated) Quarter Ended Half Year Ended Year Ended Particulars 30.09.2026 [ 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026 Unaudited | ~Unaudited | Unaudited | _Unaudited | Unaudited Audited 1 |income (2) Revenue from operations 13,562.17 12,620.43 11,890.80 26,182.60 22,601.66 47,054.70 (b) Other income. 294.42 202,61 133.82 497.03 290.12 595.12 Toral income 13,856.59 | 12,823.04 | 12,024.62 | 76,679.63 | 72,891.78 | 47,849.82 2 [Expenses () Cost of materials consumed 2,592.64 2,414.86 2,218.58 5,007.50 4,285.86 8,979.13 (b) Employee benefits expense 2,328.77 2,323.69 2,00.77 4,652.46 4,071.81 8,436.23 (©) Finance costs 210.00 216,27 216.37 42627 379.65 824.04 (@) Depreciation and amortisation expense 704.90 688.09 63477 1,392.99 1,302.93 2,708.83 (¢) Other expenses 5,952.64 5,463.66 5,368.19 11,416.30 10,233.23 21,421.04 Total Expenses 11,788.95] 11,10657 | 10,517.68 | 22,895.52| 20,273.48 | _ 47,369.27 3 [Profit before tax (1-2) 2,067.64 1,716.47 1,506.94 3,784.11 2,618.30 5,480.55 4 [Tax Expense (2) Current tax 464.00 471.00 249.00 935.00 448.00 1,258.00 (b) Deferred tax 63.39 (@7.67) 197.50 B2 341.68 36.62 Tot( a€ i) A td axj u es xt pm ee nn st o sf tax in respect of earlier year 527.- 443.. 446.- 970.- 789.- 1,2( 53 86 .. 51 02) 5 [Profit after tax (3-41 1,540.25 1,273.14 1,060.44 2,813.39 1,828.67 4,222.05 6 |Other Comprehensive income/ (Loss) (OCI) Items that will not be rectassified to profit or loss (i) Remeasurement of defined benefit plan (7.44) (1.68) (1.68) ©.12) (3.3 [Showing first 8,000 characters — download PDF for full document]